LENTE OFTÁLMICA COMPREENDENDO UM COMPOSTO DE ACRILONITRILA

The incorporation of a compound with specific absorption properties in ophthalmic lenses addresses the inefficiencies of current additives by enhancing blue light absorption, mechanical stability, and optical clarity, ensuring long-term performance.

BR112025021002A2Pending Publication Date: 2026-11-10ESSILOR INTERNATIONAL(COMPAGNIE GENERALE D OPTIQUE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025021002
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2024-04-26
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing ophthalmic lenses fail to effectively absorb blue light due to the incompatibility between the spectral properties of current light-absorbing additives, leading to issues such as impractical concentrations, compatibility problems, and degradation of mechanical properties, while also failing to maintain stable optical properties over time.

Method used

Incorporation of a compound of Formula (I) as a light-absorbing additive into the ophthalmic lens, which has a maximum absorption wavelength of 350 to 400 nm and an absorption extinction coefficient of at least 30,000 M⁻¹cm⁻¹, reducing the need for high concentrations and minimizing surface contamination during polymerization, thereby maintaining mechanical properties and optical stability.

Benefits of technology

The compound of Formula (I) provides superior blue light absorption, reduces yellowing, enhances thermomechanical properties, and maintains optical clarity and resistance over time, making it suitable for various optical applications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to ophthalmic lenses comprising a compound of Formula (I), a preparation method thereof and the use of a compound of Formula (I) in an ophthalmic lens to absorb blue light.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 53 Ophthalmic lens comprising an acrylonitrile compound. TECHNICAL FIELD

[001] The present invention relates to ophthalmic lenses comprising an acrylonitrile compound, to a method for producing said lenses and to the use of said compound in an ophthalmic lens to absorb blue light. BACKGROUND

[002] The light that reaches and enters the human eye is divided into visible light, comprising wavelengths of about 380 to 780 nm, and non-visible light, which includes light in the ultraviolet range (UV-A and UV-B light of about 280 to 380 nm) and in the infrared range (near-IR light of about 780 to 1400 nm).

[003] UV light is known to be harmful to the human eye. In particular, it can accelerate aging, which can lead to premature cataracts or more extreme disorders such as photokeratitis or snow blindness.

[004] Blue light, also known as high-energy visible light (HEV), corresponds to visible light in the blue-violet band between 380 and 500 nm. Prolonged exposure to blue light emitted by digital devices such as televisions, laptops, tablets and smartphones, and to fluorescent and LED lighting is harmful, since blue light can reach the retina.

[005] Some specific bands of blue light have been shown to cause photoretinitis; digital eye strain or computer vision syndrome, which includes blurred vision, difficulty focusing, dry and irritated eyes, headaches, neck and back pain; circadian rhythm disorder; decreased melanin production; age-related macular degeneration; glaucoma; degenerative retinal diseases; breast and prostate cancer; diabetes; heart disease; obesity and Petition 870260108441, dated 10 / 22 / 2026, p. 6 / 139 2 / 53 depression.

[006] Blue light in the range of about 420 to 450 nm is believed to be especially harmful.

[007] By incorporating light-absorbing additives into ophthalmic lenses, it is possible to prevent damage caused by UV light and blue light.

[008] To prepare light-absorbing ophthalmic lenses, three different methods can be used. The first method is the impregnation of a polymerized lens in a bath containing a light-absorbing additive. However, this method adds a step to the lens production process, which is undesirable in terms of cost and time.

[009] The second method is coating the surface of ophthalmic lenses with a substance that can absorb light rays. However, incorporating large amounts of light-absorbing additives into a coating weakens its mechanical properties.

[0010] The third method is the incorporation of a light-absorbing additive into the liquid formulation in the mass (i.e., before polymerization). However, incorporating large amounts of light-absorbing additives into the mass can lead to undesirable yellowing, as well as compatibility issues and degradation of mechanical properties.

[0011] Currently, the best commercial compounds for use in lenses are benzotriazoles and benzophenones. The main problem associated with commercial compounds stems from the fact that their spectral properties are not well suited to blue-cutting: typically, their maximum absorption wavelength (λmax) is lower than what would be necessary to achieve significant extinction within the blue-cutting range. In fact, most products available on the market exhibit a maximum absorption wavelength (λmax) equal to or less than 350 nm, leading to very weak absorption or no absorption at, and above, 400 nm. Other Petition 870260108441, dated 10 / 22 / 2026, page 7 / 139 3 / 53 compounds exhibit a maximum absorption wavelength within the blue cutoff range, but have low absorption extinction coefficients, i.e., less than 30,000 M-1cm-1, at these wavelengths.

[0012] This incompatibility between spectral properties and application in blue cut leads to two consequences: - When blue-cutting molecules are introduced into a volume with a thin dimension, such as a film or coating, the concentration required to achieve blue cutting becomes impractical or unfeasible; - When blue-cutting molecules are introduced into the melt, the concentration required to achieve blue-cutting can cause compatibility issues, such as fluorescence (the additive migrates out of the lens during polymerization and causes surface defects) or degradation of the thermomechanical properties of the matrix.

[0013] Thus, blue-cutting molecules that are effective in low quantities are needed to limit the degradation of the mechanical properties of the polymer matrix and compatibility issues.

[0014] In particular, robust lenses are needed whose optical properties remain stable over time.

[0015] It has been found that this need can be met with an ophthalmic lens comprising a compound of Formula (I), as defined herein, as a light-absorbing additive. In fact, the compound of Formula (I) can have a maximum wavelength absorption in the range of 350 to 400 nm and high absorption extinction coefficients, i.e., equal to or greater than 30,000 M-1cm-1, at these wavelengths, and can thus be used to absorb blue light more efficiently than existing commercial lenses comprising, for example, benzotriazoles and Petition 870260108441, dated 10 / 22 / 2026, p. 8 / 139 4 / 53 benzophenones.

[0016] Ophthalmic lenses comprising a compound of Formula (I) show superior blue cut performance, represented by BVC B' or UV cut, compared with commercial lenses comprising the same amount of a conventional benzotriazole; and, moreover, show low unwanted yellowing and good clarity.

[0017] Because the oxazolones of Formula (I) are more effective for blue light cutting applications, the amount of light absorber that needs to be introduced into the lens is reduced, so that the migration of light absorber on the lens surface during polymerization is minimized, resulting in less contamination of the mold surfaces and eventually eliminating the need to clean the molds between successive uses. The use of reduced amounts of blue light cutting molecules may decrease the cost of lens production.

[0018] Furthermore, substrates comprising low amounts of the compound of Formula (I) will exhibit enhanced thermomechanical properties, as the mechanical properties of a substrate are usually improved when additives and / or adjuvants are used in smaller amounts.

[0019] The lenses according to the invention also show high light resistance and maintain their optical properties over time.

[0020] Furthermore, compounds of Formula (I) can also be used in thin dimension applications, such as light filtering coatings, hard covers, films and laminates.

[0021] Additionally, compounds of Formula (I) can be encapsulated in nanoparticles and produce reduced yellowing in allylic matrices requiring high amounts of catalyst to initiate polymerization. Petition 870260108441, dated 10 / 22 / 2026, page 9 / 139 5 / 53

[0022] Finally, molecules are also needed that are effective at filtering a limited range of visible light, in order to protect the user from harmful light or improve their vision, in particular to improve perception, contrast or color discrimination (for colorblind users).

[0023] It has been found that the combination of optical properties of ophthalmic lenses according to the invention makes them particularly useful in optical applications. SUMMARY

[0024] A primary objective of the present invention is an ophthalmic lens comprising: - a plastic base and - a compound of Formula (I), or a salt thereof, X, Ri, R2, R3, FU and R5 as defined herein.

[0025] A second objective of the present invention is a process for preparing the ophthalmic lens of the invention, comprising the steps of: a) supply of monomers or oligomers from which the plastic base can be prepared, b) mixture of the monomers or oligomers, of the compound of Formula (I) as defined herein and of a suitable catalyst for the polymerization of the monomers and oligomers in order to form a polymerizable liquid composition, c) curing of the polymerizable liquid composition.

[0026] A third objective of the present invention is the use of a compound of Formula (I), as defined herein, in an ophthalmic lens to absorb blue light. Petition 870260108441, dated 10 / 22 / 2026, page 10 / 139 6 / 53

[0027] A fourth object of the present invention is a composition comprising a plastic base and a compound of Formula (IA) Ri, R2, R3, R4 and Rs being as defined herein.

[0028] A fifth objective of the present invention is the use of a composition, as defined herein, in an optical article.

[0029] A sixth objective of the present invention is the provision of new compounds chosen from among: CN or salts thereof. Detailed description Ophthalmic lens

[0030] The present invention relates to an ophthalmic lens.

[0031] As used herein, the term ophthalmic lens refers to any type of lens intended to be worn on a user's face, which may be for purposes of improving or enhancing visual acuity, for environmental protection, for fashion or adornment. The term may refer to ophthalmic lenses such as non-corrective lenses (also called plano lenses), semi-finished lens blanks and corrective lenses such as progressive addition lenses, single vision or multifocal lenses. Other examples of ophthalmic lenses include electronic lenses, virtual reality (VR) lenses, augmented reality (AR) lenses and the like. Petition 870260108441, dated 10 / 22 / 2026, p. 11 / 139 7 / 53

[0032] The ophthalmic lens of the present invention comprises a compound of Formula (I) or a salt thereof, R2Ri Ki(I) Ri is chosen from -CN, -CONH2, -CO2R6 or -SO2-(C1C12)alkyl, R2 is, independently of R3, R4 and R5, chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, -SO2R10, -NH2, -NHR11, N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (Ci-Ci2)alkyl, (C1Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (CeCi8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl(Ci-C-i2)alkyl (with 5 (10 members) R3, R4 and R5 are independently selected from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHR11, -N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (C1-C12)alkyl, (C1-C12)haloalkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, (C1-C12)heteroalkyl, (C3C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl(C1-C12)alkyl, (C6-C18)aryl(C1-C12)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(C1-C12)alkyl (with 5 to 10 members) members), Xé NH,NRi5, O ou S, Re, R7, Re, Rg, R10, R11 R12, R13 θ Ru are independently chosen from (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (Ce-C-ieJaryl, (C6-Ci8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(Ci-Ci2)alkyl (with 5 to 10 members), R15 is chosen from (C1-C12)alkyl, (C2-C12)alkenyl, (C2C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3Petition 870260108441, of 22 / 10 / 2026, page 12 / 139 8 / 53 C1-C1-C1-2)heterocycloalkyl, (C6-C1-C1-8)aryl, (C6-C1-C1-8)aryl-(C1-C1-C1-2)alkyl, heteroaryl (with 5 to 10 members), heteroaryl-(C1-C1-C1-2)alkyl (with 5 to 10 members), said alkyl being optionally substituted by one to three Rie groups, Rie is chosen from halogen atoms, (C1-C12)alkoxy, (C6-C18)aryl, or where R15 is a structure of Formula a: Rxa in which: L is (C1-C12)alkylene, Ria is chosen from among -CN, -CONH2, -CO2Rea or -SO2-(CiCi2)alkyl, R2a é, independently de Rsa, R4a e Rsa, escolhido dentre H, F, Cl, Br, I, -OH, -OR7a, -SH, -SR8a, -SOR9a, S02Rioa, -NH2, -NHRna, -N(Ri2a)2, -NHCORna, -NHSO2ORi4a, -NO2, -CN, (Ci-Ci2)alquila, (C1C-i2)haloalquila, (C2-Ci2)alquenila, (C2-Ci2)alquinila, (Ci-Ci2)heteroalquila, (C3-Ci2)cicloalquila, (C3-Ci2)heterocicloalquila, (Ce-Ciejarila, (CeCi8)aril-(Ci-Ci2)alquila, heteroarila (com 5 a 10 membris) ou heteroaryl(Ci-C-i2)alquila (with 5 to 10 members), Rsa, R4a and Rsa are independently stored in H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8a, -SOR9a, S02Rioa, -NH2, -NHRna, N(Ri2a)2, -NHCORna, -NHSO2ORi4a, -NO2, -CN, (Ci-Ci2)alquila, (C1C-i2)haloalquila, (C2-Ci2)alquenila, (C2-Ci2)alquinila, (Ci-Ci2)heteroalquila, (C3-Ci2)cycloalquila, (C3-Ci2)heterocycloalquila, (Ce-Ciejarila, (CeCi8)aryl-(Ci-Ci2)alquila, heteroaryla (with 5 to 10 members) ou heteroaryl(Ci-Ci2)alquila (with 5 to 10 members), Rea, R7a, Rea, Rga, RlOa, Rl1a, Rl2a, Rl3a Θ Rua SãO Petition 870260108441, dated 10 / 22 / 2026, page 13 / 139 9 / 53 independently chosen from (Ci-Ci2)alkyl, (C1-C12)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl, (Ce-C18)aryl(C1-C12)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(C1C12)alkyl (with 5 to 10 members).

[0033] The expression (C1-C12)alkyl refers to a linear or branched alkyl group comprising 1 to 12 carbon atoms. Group (C1-C12) linear alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl.

[0034] Branched (C1-C12)alkyl group means an alkyl group, as defined above, comprising substituents selected from the list of linear alkyl groups defined above; said linear alkyl groups may also undergo branching. Among the branched alkyl groups, tert-butyl, sec-butyl and isopropyl groups may be mentioned.

[0035] A (C1-C12)alkyl group is, in particular, a (C1Ce)alkyl group, more particularly, a (C1-C3)alkyl group and is preferably methyl or ethyl.

[0036] R6, R7, Re, R9, R10, R11, R12, R13 and R14 are, in particular, chosen independently of (C1-C12)alkyl.

[0037] -CO2R6 is, in particular, a methyl ester or ethyl ester.

[0038] -OR7 is, in particular, methoxy or ethoxy.

[0039] -SR8 is, in particular, -SCH3.

[0040] -SOR9 is, in particular, -SOCH3.

[0041] -SO2R10 is, in particular, -SO2CH3.

[0042] -NHR11 is, in particular, NHCH3 or NHCH2CH3.

[0043] -N(R12)2 is, in particular, N(CH3)2 or N(CH2CH3)2.

[0044] -NHCOR13 is, in particular, -NHCO(CH3).

[0045] -NHSO2OR14 is, in particular, NHSO2OCH3.

[0046] -NR15 is, in particular, -NR15 chosen from among -NCH3, Petition 870260108441, of 10 / 22 / 2026, p. 14 / 139 10 / 53 NCH3CH3.

[0047] R6a, R7a, R8a, R9a, Rioa, Riia Ri2a, Ri3a and Ri4a are, in particular, chosen independently of (Ci-Ci2)alkyl.

[0048] -CO2R6a is, in particular, a methyl ester or ethyl ester.

[0049] -OR7a is, in particular, methoxy or ethoxy.

[0050] -SR8a is, in particular, -SCH3.

[0051] -SOR9a is, in particular, -SOCH3.

[0052] -SO2Ri0a is, in particular, -SO2CH3.

[0053] -NHRiia is, in particular, NHCH3 or NHCH2CH3.

[0054] -N(Ri2a)2 is, in particular, N(CH3)2 or N(CH2CH3)2.

[0055] -NHCORi3a is, in particular, -NHCO(CH3).

[0056] -NHSO2ORi4a is, in particular, NHSO2OCH3.

[0057] The term (Ci-Ci2)haloalkyl refers to a (Ci-Ci2)alkyl, as defined above, substituted with 1 or more halogen atoms, in particular chosen from F or Cl. -CF3 is a particular example of a (C1-C12)haloalkyl group.

[0058] The term (Ci-Ci2)alkoxy refers to (Ci-Ci2)alkyl-O, wherein (Ci-Ci2)alkyl is as defined above. Examples of (Ci-Ci2)alkoxy are methoxy and ethoxy.

[0059] The term (C2-C12)alkenyl refers to a ((C1-C12)alkyl group, as defined above, comprising 1 or more carbon-carbon double bonds. Examples of alkenyl include ethenyl or allyl.

[0060] The term (C2-C12)alkynyl refers to a (C1-C12)alkyl group, as defined above, comprising one or more carbon-carbon triple bonds. Examples of alkynyl groups include ethinyl or propargyl.

[0061] The term (C1-C12)heteroalkyl refers to a (C1-C12)alkyl group, as defined above, further comprising in its chain a heteroatom, in particular chosen from O, NH or S. Examples include ethylene glycol groups. Petition 870260108441, dated 10 / 22 / 2026, p. 15 / 139 11 / 53 (HO-CH2-CH2-O-).

[0062] The term (C3-C12)cycloalkyl refers to a saturated cyclic carbon ring comprising 3 to 12 carbon atoms. Cycloalkyl is, in particular, a (C3-C6)cycloalkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0063] The term (C3-C12)heterocycloalkyl refers to a cycloalkyl, as defined above, further comprising a heteroatom in its ring, in particular chosen from among O and N. An example includes a tetrahydropyranyl ring.

[0064] The term (C6-C18)aryl refers to an aromatic group consisting of 6 to 18 carbon atoms in its ring. A (C6C18)aryl group is, in particular, a (C6-C12)aryl group.

[0065] Aryl is, in particular, phenyl.

[0066] An (C6-C18)aryl-(C1-C12)alkyl group refers to a (C1-C12)alkyl group, as defined above, to which an (C6-C18)aryl group is attached, as defined above. The (C6-C18)aryl-(C1-C12)alkyl group is, in particular, benzyl.

[0067] The term heteroaryl represents any monovalent radical of a monocyclic or polycyclic aromatic group with 5 to 10 members (such as a bicyclic group) comprising 1 to 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur. The heteroaryl may be optionally substituted by one or more substituents, on a carbon atom or heteroatom, said substituents being as defined above for aryl.

[0068] Heteroaryl is, in particular, pyridyl, furanyl, imidazolyl, pyrrolyl.

[0069] A heteroaryl-(C1-C12)alkyl (with 5 to 10 members) refers to a (C1-C12)alkyl, as defined above, to which a heteroaryl group is attached, as defined above.

[0070] The aryl or heteroaryl groups defined above may be Petition 870260108441, dated 10 / 22 / 2026, p. 16 / 139 12 / 53 optionally replaced by one or more substitutes, in particular by 1 or 2 substitutes, said substitutes being, in particular, chosen from among: • halogen, in particular F or Cl, • carboxylic ester, in particular methyl ester or ethyl ester, • (C1-C12)alkyl, in particular methyl, ethyl or isopropyl, • (C1-C12)alkoxy, in particular methoxy or ethoxy, • carboxylic acid, • nitrile, • amine, in particular -NH2, NHCH3, or N(CH3)2.

[0071] In one particular embodiment, the aryl or heteroaryl groups are not substituted.

[0072] According to a particular embodiment, the ophthalmic lens according to the invention comprises a compound of Formula (I), said compound of Formula (I) not being in the form of a salt.

[0073] According to a particular embodiment, the ophthalmic lens according to the invention comprises a compound of Formula (I) in the form of a salt. This may notably be the case when the compound of Formula (I) comprises at least one basic nitrogen atom, capable of forming said salt, in particular where X is N or NR15.

[0074] Alternatively, if the compound of Formula (I) comprises a carboxylic acid group, the salt of Formula (I) may be a carboxylate salt, in particular having a sodium, potassium or lithium counterion.

[0075] In particular, the salts useful in the context of the present invention are hydrochloride salts or a sulfate salt.

[0076] According to a particular embodiment, Ri and R1a are independently chosen from CN or -CO2EL Petition 870260108441, dated 10 / 22 / 2026, p. 17 / 139 13 / 53

[0077] According to a particular embodiment, R2, R2a, R3, R3a, R4, R4a, R5 and Rõa are independently selected from H or (C1-C12)alkyl, preferably H or CH3

[0078] According to a particular embodiment, R2 and R2a are H.

[0079] According to a particular modality, R4 and R4a are H.

[0080] Depending on a particular form, R3, R3a, R5 and / or Rõa is / are CH3.

[0081] According to a particular embodiment, R16 is chosen from among halogen atoms, in particular from F or Cl.

[0082] Depending on a particular embodiment, R16 is chosen from among (C1-C12)alkoxy, in particular from among methoxy or ethoxy.

[0083] According to a particular embodiment, R16 is chosen from (C6-C18)aryl, in particular phenyl.

[0084] Depending on a particular modality, X is NH or NR15, R15 is, in particular, -(C1-C12)alkyl, said alkyl being optionally substituted by one to three R16 groups, said R16 being, in particular, chosen from F, methoxy or phenyl, more in particular, -NR15 is chosen from NCH3, NCH3CH3, -N-CH2C(CH2CH3)(CH2)3CH3, -NC(CH3)3, -NCH2-CF3, N(CH2)2-phenyl, N-(CH2)4-F or N-(CH2)4-OCH3, more in particular, X is NH or NCH3.

[0085] According to a particular embodiment, the compound of Formula (I) is such that: Ri is -CN, and X is -NR15, Petition 870260108441, dated 10 / 22 / 2026, p. 18 / 139 14 / 53 Ri5 being as defined in claim 1, in particular chosen from -(C1-C12)alkyl, optionally substituted by one to three R16 groups, in particular chosen from halogen atoms, (C1-C12)alkoxy, (C6-C18)aryl, or a compound of Formula a, as defined in claim 1, wherein R1a is -CN, and R2a, R3a, R4a and Rsa are H.

[0086] According to a particular embodiment, the compound of Formula (I) is such that: Ri is -CN, R2, R3, R4, and R5 are H, and X is -NR15, R15 being as defined above, in particular chosen from -(C1-C12)alkyl, optionally substituted by one to three groups; R16, in particular chosen from halogen atoms, (C1-C12)alkoxy, (C6C18)aryl, or a compound of Formula a, as defined above, wherein R1a is -CN, and R2a, R3a, R4a and R5a are H.

[0087] It was surprisingly found that, when X is NR15, the ophthalmic lens, as revealed here, is particularly stable after long-term storage. In particular, these lenses, when stored for more than a year, retain adequate optical properties.

[0088] According to a particular embodiment, R1a is equal to Ri, R2a is equal to R2, R3a is equal to R3 and R4a is equal to R4.

[0089] According to a particular embodiment, the compound of Formula (I) is such that, when R2 is a (C6-C18)aryl or a heteroaryl with (5 to 10) members, Ri is -CONH2 or -CO2R6, R6 being as defined above.

[0090] In a particular embodiment of formula (I), R2 is chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SOR9, SO2R10, -NH2, Petition 870260108441, dated 10 / 22 / 2026, p. 19 / 139 15 / 53 -NHRu, -N(Ri2)2, -NHC0R13, -NHSO2OR14, -NO2, -CN, (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-C18)aryl-(CiCi2)alkyl or heteroaryl-(Ci-Ci2)alkyl with (5 to 10 members).

[0091] In one particular embodiment, L is chosen from propylene or butylene, in particular propylene.

[0092] According to a particular embodiment, the compound of Formula (I) has the structure of Formula (II), (III), (IV), (V), in particular of Formula (II):

[0093] If Ri is -CN, compounds (II) and (III) are structurally the same. If Ri is -CO2R6 or -CO2NH2, compounds (II) and (III) are different with respect to the stereochemistry of the double bond, which can have either a Z or E configuration. In compound (I), the stereochemistry may be such that there is a mixture of E and Z double bonds.

[0094] According to a particular embodiment, when R6 is (C2-C-i2)alkenyl, then X is S, NH or -NR15, as defined above.

[0095] In one embodiment, R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6a and R6a are not (C2-C-i2)alkenyl.

[0096] According to a particular embodiment, the compound Petition 870260108441, dated 10 / 22 / 2026, p. 20 / 139 16 / 53 The Formula (I) is chosen from among Formulas (1-1), (I-2), (I-3), (I-4), (I-5), (I-6) or (I-7):

[0097] In particular, the compound of Formula (I) is understood in the ophthalmic lens as such, meaning that the compound of Formula (I) is not covalently bonded to the plastic base.

[0098] The compound of Formula (I) comprised in the ophthalmic lens of the invention may exhibit significant absorption in the blue light range. In particular, the compound of Formula (I) may have a maximum absorption wavelength (Àmax) equal to or less than 400 nm. More particularly, the compound of Formula (I) may have a maximum absorption wavelength in the range of 350 to 400 nm, in particular 360 to 400 nm, in particular 370 to 400 nm, more particularly 370 to 395 nm.

[0099] A maximum absorption wavelength above these ranges may lead to an undesirable high yellow index of the lens in which the said compound of Formula (I) is comprised. A maximum absorption wavelength below these ranges may lead to insufficient absorption in the blue light range.

[00100] At the maximum absorption wavelength (Àmax), the compound of Formula (I) may have a molar absorption extinction coefficient (ε) equal to or greater than 30,000 M'1cm'1.

[00101] More particularly, the compound of Formula (I) may have a molar absorption extinction coefficient (ε) in the range of 30,000 to 80,000 M⁻¹cm⁻¹, more particularly in the range of 30,000 to 70,000 M⁻¹cm⁻¹. Petition 870260108441, dated 10 / 22 / 2026, p. 21 / 139 17 / 531cm'1, and even more particularly in the range of 30,000 to 45,000 M'1cm'

[00102] Àmax and ε of the compound of Formula (I) can be measured in a 20 ppm solution of the compound of Formula (I) in an organic solvent, such as ethanol, acetonitrile or tetrahydrofuran, in particular tetrahydrofuran.

[00103] The molar absorption extinction coefficient is a measure of the intensity with which a chemical species absorbs and therefore attenuates light at a given wavelength. It is an intrinsic property of the species. It is defined as the absorption-to-path length ratio of electromagnetic radiation in a given solution. This is expressed as M'1m-1. It does not depend on the concentration of the solution or the thickness traversed by the light; on the other hand, it depends on the wavelength of the incident light and the nature of the solute and solvent.

[00104] The compound of Formula (I) can be obtained by a Knoevenagel condensation according to the following scheme:

[00105] After the reaction is complete, the crude product can be purified using known techniques such as crystallization or column chromatography.

[00106] The ophthalmic lens of the invention further comprises a plastic base.

[00107] As used herein, the term plastic base refers to an exposed ophthalmic substrate, such as an unfinished, untreated or uncoated ophthalmic lens.

[00108] Preferably, the plastic base of the ophthalmic lens of the invention is transparent. As used herein, the term transparent Petition 870260108441, dated 10 / 22 / 2026, p. 22 / 139 18 / 53 is intended to signify a material having a transmission rate greater than 85%, preferably equal to or greater than 90%.

[00109] The refractive index of the plastic base may be in the range of about 1.4 to about 1.9, such as about 1.5 to about 1.9, about 1.6 to about 1.9, about 1.7 to about 1.9, about 1.8 to about 1.9, about 1.4 to about 1.8, about 1.4 to about from 1.7, from about 1.4 to about 1.6, from about 1.45 to about 1.85, from about 1.45 to about 1.75 or from about 1.5 to about 1.7, in particular from 1.49 to 1.74.

[00110] The plastic base of the ophthalmic lens of the invention can be any conventional optical substrate known in the art. In particular, the plastic base can be chosen from a thermoset or thermoplastic resin, in particular a thermoset.The resin may be chosen from resins such as polyamide, polyimide, polysulfone, polycarbonate, polyethylene terephthalate, poly(methyl(meth)acrylate), cellulose triacetate or copolymers thereof, or it may be chosen from a thermosetting resin, such as a cyclic olefin copolymer, an allylic ester homopolymer or copolymer, a linear or branched aliphatic or aromatic polyol allylic carbonate homopolymer or copolymer, a (meth)acrylic acid homopolymer or copolymer and esters thereof, a thio(meth)acrylic acid homopolymer or copolymer and esters thereof, a urethane and thiourethane homopolymer or copolymer, an epoxy homopolymer or copolymer, a sulfide homopolymer or copolymer, a disulfide homopolymer or copolymer, an episulfide homopolymer or copolymer, a polythiol and polyisocyanate copolymer, as well as as combinations thereof.

[00111] In one embodiment, the plastic base may comprise a copolymer of at least one polythiol and a polyisocyanate; preferably a copolymer of xylene diisocyanate and 1,2-bis[(2 Petition 870260108441, dated 10 / 22 / 2026, page 23 / 139 19 / 53 mercaptoethyl)thio]-3-mercaptopropane or a copolymer of bis(isocyanatomethyl)bicyclo[2.2.1]heptane, pentaerythritol tetrakis(3-mercaptopropionate) and 1,2-bis[(2-mercaptoethyl)thio]-3-mercaptopropane or a copolymer of xylylene diisocyanate and 4,8 (or 4,7 or 5,7)-dimercaptomethyl1,11-dimercapto-3,6,9-trithiaundecane.

[00112] In another embodiment, the plastic base may be a copolymer of an allylic monomer or allylic oligomer, such as diethylene glycol bis(allyl carbonate), ethylene glycol bis(allyl carbonate), diethylene glycol bis(allyl carbonate) oligomers, ethylene glycol bis(allyl carbonate) oligomers, bisphenol A bis(allyl carbonate) or diallyl phthalates, and a second monomer or oligomer that can polymerize with the allylic monomer or oligomer, such as alkyl mono(meth)acrylates, di(meth)acrylates, tri(meth)acrylates or tetra(meth)acrylates of aromatic vinyl compounds.

[00113] In the ophthalmic lens of the invention, the compound of Formula (I) may be included in the plastic base or in a separate layer coated onto a surface of the plastic base.

[00114] As used herein, a separate coating layer on a plastic base surface is defined as a coating that (i) is positioned above the substrate, (ii) is not necessarily in contact with the substrate, i.e., one or more intermediate layers may be disposed between the substrate and the layer in question, and (iii) does not necessarily completely cover the substrate.

[00115] The separate coating layer on a plastic base surface can be made of any material conventionally used to coat an ophthalmic lens. For example, the so-called separate coating layer can be obtained by polymerizing an acrylic-based coating, a sol-gel-based coating, an epoxy-based coating, or a polyurethane-based coating.

[00116] Preferably, the compound of Formula (I) is included in Petition 870260108441, dated 10 / 22 / 2026, p. 24 / 139 20 / 53 ophthalmic lens plastic base. The compound of Formula (I) can be incorporated into the plastic base by dispersing it in raw materials (monomers) before polymerization. As such, the compound of Formula (I) can be homogeneously dispersed in the ophthalmic lens plastic base. Alternatively, the compound of Formula (I) can be incorporated into the plastic base by imbibition. An imbibition method may comprise immersing the plastic base in a bath containing the compound of Formula (I) for a specified time, so that it can diffuse into the plastic base. As such, the compound of Formula (I) can be dispersed in a thin layer on the surface of the plastic base. With the imbibition method, the thickness of the plastic base incorporating the compound of Formula (I) does not depend on the overall geometry of the ophthalmic lens.

[00117] When the compound of Formula (I) is included in the plastic base, the amount thereof may be comprised in the range of 0.001 to 2%, in particular 0.001 to 1%, more particularly 0.001 to 0.1%, even more particularly 0.01 to 0.05% or 0.003 to 0.035%, by weight based on the weight of the plastic base.

[00118] When the compound of Formula (I) is included in a separate layer coated on a plastic base surface, the amount thereof may be comprised in the range of 0.001 to 2%, in particular 0.001 to 1%, more particularly in the range of 0.001 to 0.1%, even more particularly in the range of 0.01 to 0.05% or 0.003 to 0.035%, by weight based on the weight of the separate layer.

[00119] Furthermore, the compound of Formula (I) can be encapsulated within nanoparticles. Said nanoparticles can be dispersed in the plastic base of the ophthalmic lens or in a separate layer coated onto a surface of the plastic base. Preferably, said nanoparticles are dispersed in the plastic base of the ophthalmic lens, said plastic base comprising a copolymer. Petition 870260108441, dated 10 / 22 / 2026, page 25 / 139 21 / 53 including an allylic monomer or oligomer, as defined above.

[00120] The amount of the compound of Formula (I) in the nanoparticles can be understood to be in the range of 0.0001 to 90% by weight, in particular in the range of 0.01 to 50% by weight, more particularly in the range of 0.1 to 10% by weight, based on the weight of the nanoparticles.

[00121] In the context of the present invention, the term nanoparticles is intended to mean individualized particles of any shape having a size, measured in their longest direction, in the range of 1 nm to 10 μm, preferably in the range of 10 nm to 5 μm, as measured by Dynamic Light Scattering.

[00122] Nanoparticles can be polymer-based, i.e., comprise a polymer, or mineral-based, i.e., comprise a mineral oxide.

[00123] In a preferred embodiment, the polymer or mineral oxide contained in the nanoparticles is a transparent material.

[00124] The ophthalmic lens may further comprise a UV absorber other than the compound of Formula (I). In one embodiment, the ophthalmic lens may further comprise a benzotriazole UV absorber or a mixture thereof, preferably a benzotriazole UV absorber selected from 2-(2-hydroxy-5-tert-octylphenyl)-2H-benzotriazole, 2-(3-tert-butyl-2-hydroxy-5-methylphenyl)-5-chloro-2H-benzotriazole and mixtures thereof.

[00125] The benzotriazole UV absorber can be included in the plastic base or in a separate layer coated onto a surface of the plastic base.

[00126] Preferably, the benzotriazole UV absorber is included in the plastic base when the compound of Formula (I) is included in the plastic base or the benzotriazole UV absorber is included in a separate layer when the compound of Formula (I) is included in a separate layer coated on a surface of the base. Petition 870260108441, dated 10 / 22 / 2026, page 26 / 139 22 / 53 plastic.

[00127] Advantageously, the amount of benzotriazole UV absorber is less than that generally required to absorb blue light when no compound of Formula (I) is present in the ophthalmic lens. When the benzotriazole UV absorber is included in the plastic base, the total amount of benzotriazole UV absorber can be comprised in the range of 0.001 to 2%, in particular in the range of 0.01 to 1.5%, more particularly in the range of 0.1 to 1.25%, by weight based on the weight of the plastic base. When the benzotriazole UV absorber is included in a separate layer coated onto a surface of the plastic base, the total amount of benzotriazole UV absorber can be comprised in the range of 0.001 to 2%, in particular in the range of 0.01 to 1.5%, more particularly in the range of 0.1 to 1.25%, by weight based on the weight of the separate layer.

[00128] The ophthalmic lens may further comprise an additive, in particular a light stabilizer, or an anti-yellowing agent. As used herein, light stabilizer means an additive that improves the light stability of the ophthalmic lens, in particular an additive that limits the degradation of the ophthalmic lens properties by exposure to light, such as ultraviolet light. As used herein, anti-yellowing agent means an additive that limits the yellowing of the ophthalmic lens. Particularly suitable light stabilizers are sulfide anti-yellowing additives, such as dialkyl thiodipropionate or dialkyl thiodiglycolate, and hindered amine light stabilizers (HALS), such as Tinuvin® 144, Tinuvin® 1130, Tinuvin® 479, Tinuvin® 123 or Hostavin® 3058, or a mixture thereof.

[00129] The light stabilizer can be included in the plastic base or in a separate layer coated onto a surface of the plastic base. Petition 870260108441, dated 10 / 22 / 2026, p. 27 / 139 23 / 53

[00130] Preferably, the light stabilizer is included in the plastic base when the compound of Formula (I) is included in the plastic base or the light stabilizer is included in a separate layer when the compound of Formula (I) is included in a separate layer coated on a surface of the plastic base.

[00131] Advantageously, the amount of light stabilizer is comprised in the range of 0.001 to 1%, in particular in the range of 0.01 to 0.75%, more particularly in the range of 0.025 to 0.5%, by weight based on the weight of the plastic base or the separate layer coated on a surface of the plastic base.

[00132] The use of a light stabilizer is particularly desirable when the plastic base has a tendency to yellow, in particular for a homopolymer or copolymer of allyl carbonates of linear or branched aliphatic or aromatic polyols; or a copolymer of polythiol and polyisocyanate. For the latter (polythiourethanes), the use of a light stabilizer is desirable for plastic bases with a high refractive index of around 1.6, and more particularly around 1.67.

[00133] As mentioned above, the ophthalmic lens can be manufactured according to user specifications and processed in order to provide the ophthalmic lens with various functions. Accordingly, the ophthalmic lens may have a complex structure resulting from the layering of materials and / or a series of treatments to adjust the ophthalmic lens to specific user requirements. For example, treatments may be performed to reduce thickness and make the ophthalmic lens lightweight, as well as improve its transparency, for purposes of durability, strength and protection, aesthetics, etc. Consequently, an ophthalmic lens may further comprise one or more coatings disposed on the plastic base in addition to the optional separate layer which may comprise the compound of Formula (I), such as an impact-resistant coating, an anti-scratch coating, a Petition 870260108441, dated 10 / 22 / 2026, page 28 / 139 24 / 53 anti-reflective coating, a tinted coating, a colored coating, an antistatic coating, an anti-smudge coating, a water-repellent coating, a polarizing coating or a photochromic coating.

[00134] The ophthalmic lens of the invention can absorb blue light. In particular, the ophthalmic lens can exhibit a light cutoff greater than 403 nm.

[00135] In one embodiment, the ophthalmic lens may exhibit a light cutoff range of 403 to 420 nm, in particular in the range of 404 to 411 nm.

[00136] The term light cutoff, as used herein, refers to the lowest wavelength in the UV-visible range for which the transmittance through the ophthalmic lens is greater than 1%.

[00137] The term transmittance, as used herein, refers to the intensity of radiation transmitted through a material above that of the incident radiation, and is expressed as a percentage. The transmittance of the ophthalmic lens can be measured in accordance with ISO 8980-3-2003.

[00138] In one embodiment, the TVD65 transmittance of the ophthalmic lens is greater than 85%, in particular greater than 87%.

[00139] The ophthalmic lens of the invention may not exhibit undesirable yellowing. In particular, the Yellow Index, or YI, of the light transmitted through said ophthalmic lens may be less than 14. The Yellow Index of the ophthalmic lens may be measured in accordance with ASTM D-1925.

[00140] In particular, the Yellow Index of light transmitted through the said ophthalmic lens may be less than 10 in a UV cutoff of 410 nm.

[00141] The ophthalmic lens of the invention may have a BVC B' value greater than 25%, in particular greater than 30%, and more particularly greater than 35%. Petition 870260108441, dated 10 / 22 / 2026, p. 29 / 139 25 / 53

[00142] The BVC B' value refers to the blue-violet cutoff determined by excluding transmission in the 400 to 455 nm range from the total transmission in the 380 to 780 nm range (100% - average transmittance in the spectral range of 400 to 455 nm).

[00143] The ophthalmic lens according to the invention exhibits good stability.

[00144] The ophthalmic lens, as described above, may have an optical cutoff change ΔUVcutoff after exposure of the ophthalmic lens for 40 hours to light in a Q-SUN Xe-3 xenon test chamber of less than 2%, in particular less than 1%, these values ​​being absolute.

[00145] The ophthalmic lens, as described above, may have a perceived color difference ΔEιab after exposure of the ophthalmic lens for 40 hours to light in a Q-SUN Xe-3 xenon test chamber of less than 2.5, in particular less than 1.

[00146] ΔUVcut (%) denotes the optical cutoff change after accelerated aging for 40 hours (t40) in a Q-SUN Xe-3 xenon test chamber relative to the lens in its initial state (t0), expressed as a percentage: wv^y / o) = ILow^Dvl—xioo UVcut(t0)

[00147] ΔELab, denoting perceived color difference after accelerated aging for 40 hours (t40) in a Q-SUN Xe-3 xenon test chamber relative to the lens in its initial state (t0): ^ELab= V^L*)2+ (Δα*)2+ (Δb·)2 where each of the individual differences means: ΔT* = L*t40- L*w Δα* = a*t40- a*t0Δb* = b*t40- b\0L* corresponding to brightness; a* value indicating the red-green component; and Petition 870260108441, dated 10 / 22 / 2026, p. 30 / 139 26 / 53 b* value indicating yellow-blue components.

[00148] These values, colorimetric coordinates L*, a* and b*, represent colorimetric coordinates that can be measured according to the CIE (1976) international colorimetric system L*a*b*.

[00149] Furthermore, and in particular, it was found that when X in Formula (I) is NR15, the ophthalmic lens is particularly stable in the long term.

[00150] These lenses still show adequate optical properties after at least one year of storage in the dark and at room temperature. They exhibit notably after one year of storage: • an optical cutoff change ΔUVcutoff less than 0.5%, these values ​​being absolute, and / or • a perceived color difference ΔEιab less than 1, and / or • a ΔBVC B' value less than 5%. Process for preparing ophthalmic lenses.

[00151] The ophthalmic lens of the invention can be prepared using a process comprising the following steps: a) supply of monomers or oligomers from which the plastic base can be prepared; b) mixture of the monomers or oligomers, of the compound of Formula (I) and of a suitable catalyst for the polymerization of the monomers and oligomers in order to form a polymerizable liquid composition; c) curing of the polymerizable liquid composition.

[00152] A coating can be deposited or formed through various methods, including wet processing and film transfer.

[00153] In particular, the ophthalmic lens of the invention can be prepared using a wet process comprising the following steps: Petition 870260108441, dated 10 / 22 / 2026, page 31 / 139 27 / 53 a) supply of monomers or oligomers from which a coating layer can be prepared; b) mixture of the monomers or oligomers, of the compound of Formula (I) and of a suitable catalyst for the polymerization of the monomers and oligomers in order to form a polymerizable liquid composition; c) coating of the polymerizable liquid composition onto a substrate; d) curing of the polymerizable liquid composition.

[00154] Preferably, the curing is done thermally.

[00155] Alternatively, the ophthalmic lens of the invention can be prepared with a film transfer process comprising the steps of: a) supply of monomers or oligomers from which a coating layer can be prepared; b) mixture of the monomers or oligomers, of the compound of Formula (I) and of a suitable catalyst for the polymerization of the monomers and oligomers in order to form a polymerizable liquid composition; c) coating of the polymerizable liquid composition onto a transfer film; d) curing of the polymerizable liquid composition to obtain a coating layer; (e) Transfer of the coating layer from the transfer film to a substrate.

[00156] Preferably, the curing is done thermally.

[00157] Preferably, the coating layer is bonded to the substrate by an adhesive layer, such as a UV-curable adhesive, a thermally curable adhesive layer or a pressure-sensitive adhesive layer. Petition 870260108441, dated 10 / 22 / 2026, page 32 / 139 28 / 53

[00158] According to a preferred embodiment, the liquid polymerizable composition can be stirred until homogeneous and subsequently degassed and / or filtered before curing.

[00159] The polymerizable liquid composition of the present invention described above can be melted in a casting mold to form a lens and polymerized by heating to a temperature of 10 to 150 °C, in particular 15 to 130 °C. According to a preferred embodiment, the heating can last from 5 to 24 hours, preferably from 7 to 22 hours, more preferably from 15 to 20 hours.

[00160] The casting mold can then be disassembled and the lens can be cleaned with water, ethanol or isopropanol.

[00161] In the process according to the invention, a release agent can be used. A release agent prevents excessive adhesion between the lens and the casting mold by creating a barrier between the lens and the casting mold surface. In the invention, both internal and external release agents can be used. • An internal release agent is used by adding said agent to the monomer mass, for example, during step b) of the process according to the invention. Non-limiting examples of an internal release agent include monoalkyl or dialkyl phosphate, acid esters of monophosphate or diphosphate, silicone, fluorinated hydrocarbons, fatty acids, and ammonium salts. When an internal release agent is used, the agent may be present in the prepared ophthalmic lens. • An external release agent is used by coating the inner surface of the casting mold with a surface lubricant, such as siloxane or fluorinated hydrocarbon.

[00162] The ophthalmic lens may then be coated with one or more functional coatings selected from the group consisting of an impact-resistant coating, a scratch-resistant coating, a Petition 870260108441, dated 10 / 22 / 2026, page 33 / 139 29 / 53 anti-reflective coating, a tinted coating, a colored coating, an anti-static coating, an anti-smudge coating, a water-repellent coating, a polarizing coating or a photochromic coating. Use of a compound of Formula (I)

[00163] The present invention also relates to the use of a compound of Formula (I), as defined above, in an ophthalmic lens to absorb blue light.

[00164] Blue light absorption can be assessed by determining the average transmittance of the ophthalmic lens in the 420 to 450 nm range. Advantageously, the average transmittance of the ophthalmic lens in the 420 to 450 nm range is less than 85% for an uncoated lens (i.e., without anti-reflective coating). Composition comprising an acrylonitrile compound

[00165] The present invention also relates to a composition comprising a plastic base and a compound of Formula (IA): in which: Ri is chosen from -CN, -CONH2, -CO2R6 or -SO2-(C1C-12)alkyl, R2 is independently of R3, R4 and R5, chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRn, N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (Ci-Ci2)alkyl, (C1Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (Ce-Cisjaryl, (CeCi8)aryl-(Ci-Ci2)alkyl or heteroaryl-(Ci-Ci2)alkyl (with 5 to 10 members), R3, R4, and R5 are chosen independently from H, F, Petition 870260108441, dated 10 / 22 / 2026, p. 34 / 139 30 / 53 Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRu, -N(Ri2)2, -NHCOR13, -NHSO2ORu, -NO2i-CN, (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (Ce-Ciejaryl(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(CiCi2)alkyl (with 5 to 10 members), Xé NH, NRi5, O ou S, Re, Rz, Re, Rg, R10, Ri 1 R12, R13 e Ru são independentemente escolhidos dentre (Ci-Ci2)alkyla, (Ci-Ci2)haloalkyla, (C2-Ci2)alkenila, (C2-Ci2)alkynila, (Ci-Ci2)heteroalkyla, (C3-Ci2)cicloalkyla, (C3-Ci2)heterocicloalkyla, (C6-Ci8)aryla, (C6-Ci8)aryl-(Ci-Ci2)alkyla, heteroaryla (com 5 a 10 membros) ou heteroaryl-(Ci-Ci2)alkyla (com 5 a 10 membros), R15 is chosen from (C1-C12)alkyl, (C2-C12)alkenyl, (C2C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to 10 members), heteroaryl-(C1-C12)alkyl (with 5 to 10 members), said alkyl being optionally substituted by one to three Rw groups, R16 is chosen from halogen atoms, (C1-C12)alkoxy, (C6-C18)aryl, or where R15 is a structure of Formula b: R^a Ria R2aZ(b) where L is (C1-C12)alkylene, Ria is chosen from among -CN, -CONH2, -CO2Rea or -SO2-(CiCi2)alkyl, R2a is chosen independently of Rsa, R4a, and Rsa, from among Petition 870260108441, dated 10 / 22 / 2026, p. 35 / 139 31 / 53 H, F, Cl, Br, I, -OH, -ORza, -SH, -SR8a, -SOR9a, SO2Rioa, -NH2, -NHRiia, -N(Ri2a)2, -NHCORi3a, -NHSÜ2ORi4a, -NO2, -CN, (Ci-Ci2)alkyl, (CiCi2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (C6Ci8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl(Ci-Ci2)alkyl (with 5 to 10 members), R3a, R4a and Rõa are independently chosen within H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8a, -SOR9a, SO2Ri0a, -NH2, -NHRiia, N(Ri2a)2, -NHCORi3a, -NHSO2ORi4a, -NO2, -CN, (Ci-Ci2)alkyla, (CiCi2)haloalkyla, (C2-Ci2)alkenila, (C2-Ci2)alkynila, (Ci-Ci2)heteroalkyla, (C3-Ci2)cicloalkyla, (C3-Ci2)heterocicloalkyla, (C6-Ci8)aryla, (C6Ci8)aryl-(Ci-Ci2)alkyla, heteroaryla (com 5 a i0 membros) ou heteroaryl(Ci-Ci2)alkyl (with 5 to 10 members), R6a, R7a, R8a, R9a, Ri0a, Riia, Ri2a, Ri3a and Ri4a are independently selected from (C1-C12)alkyl, (C1-C12)haloalkyl, (C2C12)alkenyl, (C2-C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to i0 members) or heteroaryl-(C1-C12)alkyl (with 5 to i0 members), wherein the aryl or heteroaryl groups are optionally substituted by one or more substituents, in particular by i or 2 substituents, said substituents being, in particular, selected from: • halogen, in particular F or Cl, • carboxylic ester, in particular methyl ester or ethyl ester, • (C1-C12)alkyl, in particular methyl, ethyl or isopropyl, • (C1-C12)alkoxy, in particular methoxy or ethoxy, • carboxylic acid, • nitrile, • amine, in particular -NH2, NHCH3, or N(CH3)2, Petition 870260108441, dated 10 / 22 / 2026, p. 36 / 139 32 / 53 where the plastic base is as defined above.

[00166] The present invention also relates to the use of a composition, as defined above, in an optical article.

[00167] The use according to the invention, in particular, relates to optical articles, such as optical lenses, display devices, optical filters, glass, adhesives and protective films, in particular ophthalmic lenses, or display devices, such as computer or TV screens.

[00168] In particular, the composition according to the invention is used in said optical article to absorb blue light.

[00169] The present invention also relates to a new compound chosen from: or you leave them.

[00170] The invention will be described in greater detail below with the following examples which are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way.

[00171] The invention will be described in greater detail below with the following Figure and the following examples which are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way. Figure

[00172] Figure 1 represents a graph of absorbance (A) as a function of wavelength (λ, in nm) for a 20 ppm solution of the compound of Formulas (1-1) to (I-7) in tetrahydrofuran. EXAMPLES Petition 870260108441, dated 10 / 22 / 2026, p. 37 / 139 33 / 53 Measurement methods for optical performance and light resistance of lenses

[00173] The optical properties of the lenses were measured on plano lenses with a central thickness of 2 mm using a Cary60 UV-Vis spectrophotometer and a scanning wavelength of 280 to 780 nm and performing the photoaging test in Q-Sun (40 h, light power of 0.68 W / m2). The optical values ​​include UVcut, TvD65, YI, C*, h*, a*, b* and BVC B'. • UV cutoff is determined under normal incident light by plotting the percentage of lens transmittance as a function of wavelength. The UV cutoff of the material can be read from the graph as the shortest wavelength in the spectrum for which the transmittance through the ophthalmic lens is greater than 1%. • TVD65 is determined under normal incident light (standard illuminant D65). • BVC B' is determined by excluding transmission in the 400 to 455 nm range from the total transmission in the 380 to 780 nm range (100% - average transmittance in the spectral range of 400 to 455 nm). • Yield is measured according to ASTM D1925. • The colorimetric coordinates L*, a*, b*, C* and h* of the lenses of the invention were measured according to the CIE (1976) international colorimetric system L*a*b* and the international colorimetric system L*C*h* with a D65 source and a 10° observer; The measured parameters are: L* corresponding to brightness; a* value indicating the red-green component; b* value indicating yellow-blue components; C*, the chroma, representing color saturation; eh* representing the angle on the chromaticity axes.

[00174] The lightfastness test using the Q-sun test was performed in Petition 870260108441, dated 10 / 22 / 2026, pp. 38 / 139 34 / 53 plano lenses with a central thickness of 2 mm and in the Q-sun Xe-1 model: 0.68 W / m2 light intensity at 340 nm, temperature at 60 °C, Q-UV daylight filter and 40 h duty cycle. The lightfastness of the lenses was qualified in two main aspects: optical cutoff change of the lens (ΔUVcutoff) and color evolution (ΔELab). The values ​​were obtained by comparing the values ​​measured after manufacturing (t0) and the values ​​after accelerated aging for 40 hours (t40) in the Qsun cell. Materials

[00175] The following compounds are used in the examples: Petition 870260108441, dated 10 / 22 / 2026, pp. 39 / 139 35 / 53 Table 1 Function Chemical Substance CAS No. Supplier Monomer ISO1 (diisocyanate) bis(isocyanatomethyl)bicyclo[2.2.1]heptane 74091-64-8 Mitsui Chemicals Monomer THIO1 (polythiol) pentaerythritol tetrakis(3-mercaptopropionate) 7575-23-7 Mitsui Chemicals Monomer THIO2 (polythiol) 1,2-bis[(2-mercaptoethyl)thio]-3-mercaptopropane 131538-00-6 Mitsui Chemicals Monomer ISO2 (diisocyanate) xylylene diisocyanate 3634-83-1 Mitsui Chemicals Catalyst Dimethyltin dichloride (DMC) 753-73-1 Honjo Chemical Release agent Zelec® UN - Stepan Company UV Absorber (benzotriazole) Seesorb® 703 3896-11-6 Shipro Kasei Kaisha UV Absorber (benzotriazole) Seesorb® 709 3147-75-9 SC Organic Chemical Co.UV Absorber (benzotriazole) Seesorb® 701 2440-22-4 Shipro Kasei Kaisha UV Absorber (H-Oxa) Hippuric acid-benzaldehyde azalactone 17606-70-1 Eurofins UV Absorber (benzotriazole) Tinuvin® 928 73936-91-1 BASF 3,5-Dimethyl-1H-pyrrole-2-carboxaldehyde 2199-58-8 pyrrole-2-carboxaldehyde 1003-29-8 1-Methyl-1H-pyrrole-2-carboxaldehyde 1192-58-1. Petition 870260108441, dated 10 / 22 / 2026, page 40 / 139 36 / 53 Function Chemical substance CAS No. Supplier 5-Methyl-1H-pyrrole-2-carboxaldehyde 1192-79-6 Ethyl cyanoacetate 105-56-6 Malonitrile 109-77-3 2-ethylhexyl bromide 18908-66-2 1,3-dibromopropane 109-64-8 Example 1: preparation of compounds (1-1) to (I-7)

[00176] The following compounds (1-1) to (I-7) were prepared by a Knoevenagel condensation. 1-1 12 I 3 Preparation of 1-1

[00177] Compound 1-1 was prepared according to the following reaction scheme: CO2Et Piperidine EtOH r1

[00178] In summary, 3,5-dimethyl-1H-pyrrole-2-carbaldehyde was reacted with ethyl cyanoacetate in ethanol at room temperature in the presence of piperidine. I-2 Preparation

[00179] Compound I-2 was prepared using the same reaction conditions as compound 1-1, but replacing the cyanoacetate reagent. Petition 870260108441, dated 10 / 22 / 2026, page 41 / 139 37 / 53 ethyl to malononitrile. Preparation of 1-3

[00180] Compound I-3 was prepared according to the following reaction scheme: I-3

[00181] In summary, pyrrole-2-carboxaldehyde was reacted with malonitrile in water at room temperature. I-4 Preparation

[00182] Compound I-4 was prepared using the same reaction conditions as compound I-3, but replacing the pyrrole-2-carboxaldehyde reagent with 1-methyl-1H-pyrrole-2-carboxaldehyde. I-5 Preparation

[00183] Compound I-5 was prepared using the same reaction conditions as compound I-3, but replacing the pyrrole-2-carboxaldehyde reagent with 5-methyl-1H-pyrrole-2-carboxaldehyde. I-6 Preparation

[00184] Compound I-6 was prepared using the same reaction conditions as compound I-3, but replacing the pyrrole-2-carboxaldehyde reagent with 1-(2-ethylhexyl)-1H-pyrrole-2-carboxaldehyde. The latter was prepared by alkylation of 1H-pyrrole-2-carboxaldehyde with 2-ethylhexyl bromide in dimethylformamide, in the presence of sodium hydride. Preparation of I-7 Petition 870260108441, dated 10 / 22 / 2026, page 42 / 139 38 / 53

[00185] Compound I-7 was prepared by alkylation of pyrrole-2-carboxaldehyde with 1,3-dibromopropane, resulting in the substitution of the 2 bromide groups. The 2 aldehyde groups were then reacted using the same reaction conditions as compound I-3 to form the compound of Formula I-7: OMSO. C^CO, --Step 2 Example 2: Absorption properties of compounds (1-1) to (I-7)

[00186] The absorbance (A) as a function of wavelength (λ) was measured for a solution of 0.02 mg of the compound of formulas (1-1) to (I-7) in 1 mL of tetrahydrofuran. The resulting absorption spectra are shown in Figure 1.

[00187] The maximum absorption wavelength (λmax) θ and the absorption extinction coefficients (ε) at the maximum absorption wavelength are provided in Table 2 below for each compound: Table 2: Absorption data of the inventive compounds Absorption-THF Compound Àmax (nm) 360 to 400 nm £ (in Àmax) >30,000 M-1cm-1 1-1 389 40954 I-2 392 37821 I-3 370 37034 I-4 378 35393 I-5 391 41282 I-6 379 31155 I-7 377 69759 Η-Oxa: comparison 383 26788 Petition 870260108441, dated 10 / 22 / 2026, p. 43 / 139 39 / 53 Absorption-THF Compound Δmax (nm) 360 to 400 nm € (at Δmax) >30,000 M-1cm-1 Seesorb® 703: benzotriazole comparison 353 17500

[00188] All compounds according to the invention exhibit a maximum absorption wavelength (λmax) in the range of 360 to 400 nm. Furthermore, the compounds according to the invention show higher extinction coefficients at the maximum absorption wavelength compared to the prior art H-Oxa and Seesorb® 703 compounds. Example 3: preparation of compositions to obtain ophthalmic lenses with a refractive index of 1.67

[00189] Compositions 1 to 8 according to the invention and comparative compositions Comp. 1 to 3 comprising the following ingredients were prepared. The values ​​expressed in Table 3 are weight percentages based on the total weight of the compositions. Petition 870260108441, dated 10 / 22 / 2026, page 44 / 139 40 / 53 Table 3: Compositions for ophthalmic lenses with a refractive index of 1.67 Examples according to the invention Comparative examples Composition (%) 1 2 3 4 5 6 7 8 Comp. 1 Comp. 2 Comp. 3 ISO2 51.389 51.390 51.387 51.385 51.388 51.390 51.386 51.386 51.376 51.371 51.061 THIO2 47.284 47.285 47.283 47.281 47.284 47.285 47.282 47.282 47.272 47.268 46.983 Stan DMC 0.010 0.010 0.010 0.010 0.010 0.010 0.010 0.010 0.010 0.010 0.010 Zelec® UN 0.079 0.079 0.079 0.079 0.079 0.079 0.079 0.079 0.079 0.079 0.078 Seesorb® 701 P-UV absorber 1.233 1.233 1.233 1.233 1.233 1.233 1.233 1.233 1.233 1.233 I-1 0.004 I-2 0.002 I-3 0.008 0.012 I-4 0.006 I-5 0.003 I-6 0.010 I-7 0.010 H-Oxa 0.030 0.039 Seesorb® 709 1.667 Seesorb® 703 0.201 Total 100,000 100,000 100,000 100,000 100,000 100,000 100,000 100,000 100,000 100,000 100,000 Petition 870260108441, dated 10 / 22 / 2026, p. 45 / 139 41 / 53

[00190] The compositions were prepared according to the following steps: 1) The release agent (Zelec® UN), the catalyst (DMC), the UV absorbers (Seesorb® 701) and the blue cutting molecule of Formula (I) were dissolved in ISO2 monomer in a Duran® flask at room temperature. After becoming homogeneous, the mixture was degassed under vacuum; 2) The resulting mixture was pre-cooled to 2 °C and placed in an atmosphere of N2; 3) The THIO2 monomer was added and the mixture was stirred at 2 °C until a homogeneous mixture was formed, followed by degassing and purging with N2 before the monomer filling steps. Example 4: Preparation of ophthalmic lenses with a refractive index of 1.67

[00191] Flat glass molds were assembled using the tape bonding method to accommodate lenses with a central thickness of 2 mm. The monomer mixture from Example 3 was then injected into the prepared assembly using a clean, thermally polymerized syringe using a specific temperature profile, as shown in Table 4. Table 4: Temperature profile for BCT lenses with a refractive index of 1.67 SEGMENT 1 2 3 4 5 6 7 8 9 10 Duration (h) 0.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Start T° (°C) 20.0 20.0 20.0 20.1 20.3 20.5 21.0 21.7 22.9 24.8 End T° (°C) 20.0 20.0 20.1 20.3 20.5 21.0 21.7 22.9 24.8 28.1 SEGMENT 11 12 13 14 15 16 17 18 19 20 / Maintain Duration (h) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 7.0 Initial Temperature (°C) 28.1 33.4 42.2 56.7 80.6 120.0 120.0 120.0 90.0 75.0 Final Temperature (°C) 33.4 42.2 56.7 80.6 120.0 120.0 120.0 90.0 75.0 75.0 Petition 870260108441, dated 10 / 22 / 2026, page 46 / 139 42 / 53

[00192] The lenses were usually disassembled from the molds and subjected to the traditional cleaning and annealing processes. Example 5: preparation of compositions to obtain ophthalmic lenses with a refractive index of 1.6

[00193] Compositions 9 to 14 according to the invention and comparative compositions Comp. 4 to 6 comprising the following ingredients were prepared. The values ​​expressed in the table below are weight percentages based on the total weight of the composition. The values ​​expressed in Table 5 are weight percentages based on the total weight of the composition.

[00194] The preparation process for these compositions was the same as for compositions 1 to 8 of example 3, in that all additives were dissolved in ISO1 Monomer and then degassed and pre-cooled before the addition of THIO1 and THIO2 monomers. Table 5: Compositions for ophthalmic lenses with a refractive index of 1.6 Inventive examples Comparative examples Composition (%) 9 10 11 12 13 14 Comp. 4 Comp. 5 Comp. 6 ISO1 49.93 49.93 49.92 49.92 49.93 49.93 49.85 49.83 49.02 THIO1 23.59 23.59 23.58 23.58 23.59 23.59 23.55 23.54 23.15 THIO2 25.16 25.16 25.16 25.16 25.16 25.16 25.12 25.11 24.70 Stan DMC 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 Zelec® UN 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 Seesorb® 709 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.94 Seesorb® 703 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.12 I-1 0.01 I-2 0.01 I-3 0.030 0.035 I-4 0.010 Petition 870260108441, dated 10 / 22 / 2026, page 47 / 139 43 / 53 Inventive Examples Comparative Examples Composition (%) 9 10 11 12 13 14 Comp. 4 Comp. 5 Comp. 6 I-5 0.010 H-Oxa 0.172 0.222 Tinuvin 0.969 Total 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 Example 6: preparation of ophthalmic lenses with a refractive index of 1.6

[00195] Ophthalmic lenses having a refractive index of 1.6 were prepared using the same procedure as lenses having a refractive index of 1.67, according to example 4. The specific temperature profile is as shown in Table 6. Petition 870260108441, dated 10 / 22 / 2026, page 48 / 139 44 / 53 Table 6: Temperature profile for BCT lenses with a refractive index of 1.6 SEGMENT 1 2 3 4 5 6 7 8 9 10 11 12 Duration (h) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Start T° (°C) 15.0 15.1 15.2 15.4 15.7 16.2 17.0 18.4 20.6 22.0 27.0 34.0 End T° (°C) 15.1 15.2 15.4 15.7 16.2 17.0 18.4 20.6 22.0 27.0 34.0 45.0 SEGMENT 13 14 15 16 17 18 19 20 21 22 23 Duration (h) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 500.0 Initial Temperature (°C) 45.0 60.0 80.0 105.0 130.0 130.0 130.0 130.0 120.0 120.0 120.0 Final Temperature (°C) 60.0 80.0 105.0 130.0 130.0 130.0 130.0 120.0 120.0 120.0 120.0 Petition 870260108441, dated 10 / 22 / 2026, page 49 / 139 45 / 53

[00196] The lenses were usually disassembled from the molds and subjected to the traditional cleaning and annealing processes. Example 7: Optical properties of lenses

[00197] The BCT lenses of examples 4 and 6 were optically characterized at the initial lens stage and after the photoaging test.

[00198] The initial optical characteristics of lenses having a refractive index of 1.67 are shown in Table 7 below: Table 7: Comparison of the optical properties of BCT lenses having a refractive index of 1.67 at the beginning. Initial Stage Lenses UV Cor Te TvD6 5 YI L* a* b* C* h* BVC B' (%) Inventive 1 0.004 409 87.8 11.5 95.0 -4.6 9.6 10.6 115.9 53.5 2 0.002 404 87.7 9.8 94.9 -4.0 8.2 9.1 115.9 48.5 3 0.008 408 88.1 6.0 95.1 -2.5 5.2 5.8 115.9 36.0 4 0.012 410 88.1 7.0 95.1 -3.0 6.1 6.8 116.1 39.9 5 0.006 411 87.8 9.5 95.0 -4.0 8.1 9.0 116.0 48.7 6 0.003 408 87.8 12.0 95.0 -4.8 9.9 11.0 115.9 54.7 7 0.01 412 88.0 10.2 95.1 -4.2 8.6 9.6 116.0 50.3 8 0.01 411 87.9 10.5 95.0 -4.2 8.8 9.7 115.4 50.0 Comparative Comp 1 0.030 408 87.8 5.7 95.0 -2.4 4.9 5.5 115.6 34.9 Comp 2 0.040 410 88.0 6.2 95.1 -2.7 5.4 6.1 116.0 37.1 Comp 3 0.201 407 88.1 6.8 95.1 -2.9 5.8 6.5 116.0 38.6

[00199] The results of the photoaging tests of lenses having a refractive index of 1.67 are shown in Table 8 below: Petition 870260108441, dated 10 / 22 / 2026, page 50 / 139 46 / 53 Table 8: Comparison of the evolution after the photoaging test of BCT lenses having a refractive index of 1.67 Evolution (Q-sun, 40 h) Lenses \UVcortc(%) ΔE Inventive 1 -0.5 2.4 2 0.0 0.4 3 0.0 0.2 4 0.0 0.1 5 0.0 0.2 6 0.0 0.2 7 0.0 0.1 8 -1.0 1.5 Comparative Comp. 1 -1.0 1.1 Comp. 2 -0.7 0.8 Comp. 3 0.0 0.1

[00200] The lenses according to the invention, having a refractive index of 1.67, outperform comparative lenses in two ways: 1) Lower consumption of molecules in the same optical section due to the high absorption extinction coefficient; and 2) Superior light resistance in both aspects, i.e., optical cutoff and color retention. Meanwhile, with regard to the new lenses, it maintains excellent aesthetics comparable to the reference lenses. Specifically, example 3 doped with I-3 needed an absorber content approximately 3.7 times lower than that of the comparative Comp. 1 and even lower compared to Comp. 3 to accommodate the same optical cutoff performance (408 nm) with a similar residual color range YI (5-6), without compromising aesthetics. Moreover, the durability of example 3's photoaging property, defined by the degree of optical cutoff %ΔUVcutoff 1) and color shift (ΔE j), is greater than that of Comp. 1. Petition 870260108441, dated 10 / 22 / 2026, p. 51 / 139 47 / 53

[00201] The initial optical characteristics of lenses having a refractive index of 1.6 are shown in Table 9 below: Table 9: Comparison of the optical properties of BCT lenses having a refractive index of 1.6 at the beginning. Initial Stage Lenses Content (% by weight) UV Cut TvD6 5 YI L* a* b* C* h* BVC B' (%) Inventive 9 0.010 416 89.7 12.0 95.8 -5.1 10.2 11.4 116.5 55.6 10 0.010 416 89.5 12.5 95.7 -5.2 10.5 11.7 116.5 56.8 11 0.030 410 89.9 6.0 95.9 -2.8 5.5 6.2 117.1 36.5 12 0.033 411 89.9 6.2 95.9 -2.9 5.7 6.4 117.2 37.7 13 0.010 411 89.8 7.4 95.8 -3.4 6.7 7.5 117.1 42.1 14 0.010 417 89.8 13.0 95.8 -5.5 11.0 12.2 116.5 58.3 Comparative Comp. 4 0.175 411 89.9 6.0 95.9 -2.8 5.5 6.1 117.0 36.1 Comp. 5 0.225 412 89.7 6.7 95.8 -3.1 6.1 6.8 116.9 38.9 Comp. 6 0.120 407 89.8 5.3 95.9 -2.4 4.7 5.3 116.8 33.0

[00202] The results of the photoaging tests of lenses having a refractive index of 1.6 are shown in Table 10 below: Table 10: Comparison of the evolution after the photoaging test of BCT lenses having a refractive index of 1.6 Evolution (Q-sun, 40 h) Lenses ΔUVcut (%) ΔE Inventive 9 -0.2 0.7 10 0.0 0.2 11 0.0 0.2 12 0.0 0.1 13 0.0 0.1 14 0.0 0.1 Petition 870260108441, dated 10 / 22 / 2026, page 52 / 139 48 / 53 Evolution (Q-sun, 40 h) AUV Lens Cutoff (%) ΔE Comparison Comp. 4 -0.5 1.2 Comp. 5 -0.2 1.5 Comp. 6 0.0 0.0

[00203] In line with lenses having a refractive index of 1.67, the lenses according to the invention having a refractive index of 1.6 are more economical at the industrial level, i.e., a lower absorber content is required in the same cut-off range, in addition to having greater light resistance relative to some comparative lens examples. Example 8: Optical properties of lenses

[00204] In this example, the long-term stability of the lenses was studied.

[00205] In addition, the thermal stability and photostability of the lenses were studied after long-term storage. Example 8a: preparation of lenses for storage studies

[00206] Lenses with a refractive index of 1.67 were prepared according to the procedure described in example 3.

[00207] The lenses prepared in this example included the following compounds:

[00208] The lens composition is as shown in Table 11. Petition 870260108441, dated 10 / 22 / 2026, page 53 / 139 49 / 53 Table 11: Compositions for ophthalmic lenses with a refractive index of 1.67 Composition (%) 15 16 17 18 19 Comp-7 ISO2 51.388 51.388 51.387 51.386 51.390 51.351 THIO2 47.284 47.283 47.283 47.282 47.285 47.249 Stan DMC (ppm) 0.010 0.010 0.010 0.010 0.010 0.010 Zelec® (ppm) 0.079 0.079 0.079 0.079 0.079 0.079 Seesorb®701 UV-absorbing 1.233 1.233 1.233 1.233 1.233 1.232 I-3 0.010 I-4 0.006 I-5 0.003 I-6 0.007 I-7 0.008 H-Oxazolone-1 0.079 Total 100,000 100,000 100,000 100,000 100,000 Example 8b: initial lens properties before storage

[00209] The optical characteristics of the lenses as described in example 8a, Table 11, in the initial state, were determined using the procedure as described above, in the same way as for example 3. The results are shown in Table 12 below. Table 12: Initial optical properties of BCT lenses having a refractive index of 1.67 Initial Optical Properties Lenses UVc Content (% by weight) TvD6 5 YI L* a* b* C* h* BVC B' (%) 15 0.006 411 87.8 9.4 95.0 -3.9 8.0 8.9 116.0 48.2 16 0.007 411 87.9 9.5 95.0 -4.0 8.1 9.0 116.1 48.3 17 0.008 412 87.8 11.0 95.0 -4.4 9.2 10.2 115.6 51.8 18 0.010 409 88.1 6.4 95.1 -2.7 5.6 6.2 115.9 37.4 19 0.003 409 88.0 11.9 95.0 -4.8 9.9 11.0 116.1 54.6 Petition 870260108441, dated 10 / 22 / 2026, page 54 / 139 50 / 53 Initial Optical Properties Lenses UVc Content (% by weight) TvD6 5 Yl L* a* b* C* h* BVC B' (%) Comp7 0.080 413 88.0 7.7 95.1 -3.3 6.8 7.5 116.3 42.9 Example 8c: Lens properties after storage - general observations and methods

[00210] The lenses from example 8a, after casting and post-curing, were stored in the dark at room temperature, inside an enclosure for about 1.2 years, and the optical properties were measured again using a UV-vis spectrometer.

[00211] The stability of the lens properties after storage was examined in terms of color change, using the AEiab parameter, as well as the change in blue cut capability, using ABVCB' and AUVcut.

[00212] When AEcab < 1%, it is defined here as an acceptable / insignificant change.

[00213] When ABVCB' < 5%, it is defined as an acceptable / insignificant change.

[00214] When AUVcut < 0.5%, it is defined here as an acceptable / insignificant change.

[00215] For the experiments described here, AEiab, ABVCB' and AUVcorte were calculated as follows. • General calculation for the amplitude of the color change (equation a) ^Lab = V(AL*)2+ (Aa*)2+ (Ab*)2(Equation a) where: ΔΓ = r(0Δα* = α*ω- a\io}- b\io) Petition 870260108441, dated 10 / 22 / 2026, page 55 / 139 51 / 53 io denotes the value at the initial stage and ei denotes the value after 1.2 years of storage. • General calculation of the amplitude of the change in cutting performance (equation b) ΔΒν#Β'(%) = ^ΧΞΙαε^ΧΞ^x^θ (Equation b) BVCB'^) ío denotes the value at the initial stage and ei denotes the value after 1.2 years of storage. • General calculation of the amplitude of the change in cutting performance (equation c) AUVcorte(%) = ' ,' '<:x100 (Equation c)+ Vcorte^io) io denotes the value at the initial stage and ei denotes the value after 1.2 years of storage. Thermal stability tests of stored lenses

[00216] Lenses stored for 1.2 years or more were analyzed using a UV-Vis spectrometer and then subjected to heating at 95 °C for 3 h, simulating the thermal conditions of the hard coating process. Subsequently, the lenses were cooled and left at room temperature for at least 1 hour to relax. Then, the optical properties of the tested lenses were measured again using the UV-Vis spectrometer.

[00217] The color shift and cut performance of the lenses 1.2 years after the thermal test were represented by the parameters previously described (ΔELab, ΔBνϋB' and ΔUVcut), using equations a, b and c.

[00218] The general equations a, b and c were adapted to calculate these parameters.

[00219] i0 refers to the value of the lenses at 1.2 years (measured immediately before the thermal test) ei refers to the value after the thermal test. Petition 870260108441, dated 10 / 22 / 2026, page 56 / 139 52 / 53 Photostability test of stored lenses

[00220] The properties of lenses stored under photoaging were examined to predict the robustness of aged lenses during use.

[00221] The photoaging test was performed using the Q-sun test, as described above (for 80 hours).

[00222] Similarly, the optical properties of these lenses stored for 1.2 years were measured before and after an 80 h cycle of the Q-sun test to determine the degree of color change and cut performance throughout the test. The degree of change was quantified following equations a, b, and c, respectively, where io refers to the value of the lenses at 1.2 years (measured immediately before the Q-sun test) and ei refers to that of the lenses after an 80 h cycle of the Q-sun test. Example 8d: Storage stability test results

[00223] The results of the thermal tests and phototests above are shown in Table 13. Table 13: Results of storage / stability experiments Test I: Dark Storage (1.2 years) II: Thermal Stability of Lenses at 1.2 Years III: Photostability of Lenses at 1.2 Years Absorber δε <1 δβVCB' (%) <5% ΔUVc Cut (%) <0.5% ΔE <1 δβVCB' (%) <5% ΔUVc Cut (%) <0.5% ΔE <1 δβVCB' (%) <5% ΔUVc Cut (%) <0.5% 15 I-4 0.5 3.4 0.00 0.4 1.0 0.0 0.3 -2.0 -0.2 16 I-6 0.3 2.5 0.00 0.2 0.5 0.0 0.3 -0.9 -0.2 17 I-7 0.3 0.4 0.00 0.3 0.6 0.0 2.0 -1.0 -1.0 18 I-3 NA NA NA 1.5 4.9 0.0 0.6 -3.2 -0.1 19 I-5 NA NA NA NA NA NA NA NA Comp-7 Oxazolone 0.3 2.5 -0.20 1.5 -13.5 -0.5 3.0 -33.8 -2.3

[00224] From Table 13, it can be concluded that lenses 15 to 18, according Petition 870260108441, dated 10 / 22 / 2026, page 57 / 139 53 / 53 with the invention, generally showed better thermal stability and photostability after storage (tests II and III), compared with lenses comprising oxazolone.

[00225] In particular, lenses made up of compounds I-4, I-6 and I-7 showed particularly high stability.

[00226] It has been shown that these lenses, comprising substituted N-alkyl pyrrole-acrylonitrile, are particularly stable under storage conditions and post-thermal stability and photostability when compared with lenses comprising oxazolone and lenses comprising unsubstituted nitrogen pyrrole-acrylonitrile (I-3 and I-5).

[00227] Specifically, the lenses fused with substituted N-alkyl I-4 and I-6 exhibited high robustness in all aspects; acceptable color and cutability over time and post-conditioning, i.e., thermal stability and photostability steps after the aging period. Petition 870260108441, dated 10 / 22 / 2026, page 58 / 139

Claims

1 / 10 CLAIMS 1. Ophthalmic lens, characterized by comprising: - a plastic base, and - a compound of Formula (I) or a salt thereof, in particular a hydrochloride salt or a sulfate salt r2 Rt 3N Rj-^V^Rí (I) wherein: Ri is chosen from -CN, -CONH2, -CO2R6 or -SO2-(C1C12)alkyl, R2 is, independently of R3, R4 and R5, chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRn, N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (C1C12)alkyl, (C1C12)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (Ce-Cijaryl), (CeCi8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl(Ci-Ci2)alkyl (with 5 to 10 members), R3, R4 and R5 are independently selected from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRn, -N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl,(Ci-Ci2)heteroalkyl, (C3Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (Ce-C-ieJaryl, (C6-C-18)aryl(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(CiCi2)alkyl (with 5 to 10 members), X is NH, NR15, O or S, Re, R7, Re, Rg, R10, R11, R12, R13 θ Ru are independently chosen from (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-C18)aryl, (C6-C18)aryl-(C1-C12)alkyl, Petition 870260108441, of 10 / 22 / 2026, page 59 / 139 2 / 10 heteroaryl (with 5 to 10 members) or heteroaryl-(C1-C12)alkyl (with 5 to 10 members), Ris is chosen from (C1-C12)alkyl, (C2-C12)alkenyl, (C2C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C1-C12)aryl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to 10 members), heteroaryl-(C1-C12)alkyl (with 5 to 10 members), said alkyl being optionally replaced by one to three Rw groups,Rie is chosen from halogen atoms, (C1-C12)alkoxy, (C6-C18)aryl, or wherein R15 is a structure of Formula a: z(a) in which L is (C1-C12)alkylene, Ria is chosen from -CN, -CONH2, -CO2Rea or -SO2-(C1C12)alkyl, R2a is, independently of Rsa, R4a and Rsa, chosen from H, F, Cl, Br, I, -OH, -OR7a, -SH, -SR8a, -SOR9a, S02Rioa, -NH2, -NHRna, -N(Ri2a)2, -NHCORna, -NHSO2ORi4a, -NO2, -CN, (C1-C12)alkyl, (C1C12)haloalkyl, (C2-C12)alkenyl, (C2-C-i2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (Ce-Ciejaryl, (CeCi8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl(Ci-C-i2)alkyl (with 5 to 10 members), Rsa, R4a and Rsa are independently chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8a, -SOR9a, S02Rioa, -NH2, -NHRna, N(Ri2a)2, -NHCORna, -NHSO2ORi4a, -NO2, -CN, (Ci-Ci2)alkyl, (C1C-i2)haloalkyl, (C2-Ci2)alkenyl, (C2-C-i2)alkynyl, (Ci-C-i2)heteroalkyl, (C3-Ci2)cycloalkyl,(C3-Ci2)heterocycloalkyl, (Ci-Ci2)aryl-(Ci-Ci2)alkyl, (Ci-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (Ci-Ci2)haloalkyl, (C2Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(C1-C12)alkyl (with 5 to 10 members), wherein the aryl or heteroaryl groups are optionally substituted by one or more substituents, in particular by 1 or 2 substituents, said substituents being, in particular, chosen from: • halogen, in particular F or Cl, • carboxylic ester, in particular methyl ester or ethyl ester, • (C1-C12)alkyl, in particular methyl, ethyl or isopropyl, • (C1-C12)alkoxy, in particular methoxy or ethoxy,• carboxylic acid, • nitrile, • amine, in particular -NH2, NHCH3, or N(CH3)2.

2. Ophthalmic lens, according to claim i, characterized in that Ri and Ria are independently selected from -CN or -CO2Et, and / or in that R2, R2a, R3, R3a, R4, R4a, R5 and R5a are independently selected from H or (Ci-Ci2)alkyl, preferably H or CH3.

3. Ophthalmic lens, according to claim i or 2, characterized in that X is NH or NRi5, in particular NH or -NCH3, NCH3CH3, -N-CH2C(CH2CH3)(CH2)3CH3, -NC(CH3)3, -NCH2-CF3, N(CH2)2-phenyl, N-(CH2)4-F or N-(CH2)4-OCH3, Ri5, as defined in claim i. Petition 870260108441, dated 10 / 22 / 2026, p. 61 / 139 4 / 10 4. Ophthalmic lens, according to any one of claims 1 to 3, characterized in that the compound of Formula (I) is such that: R-ι is -CN, and X is -NRi5j Ris, as defined in claim 1, in particular chosen from -(C1-C12)alkyl, optionally substituted by one to three Rw groups, in particular chosen from halogen atoms, (C1C12)alkoxy, (C6-C18)aryl, or a compound of Formula a, as defined in claim 1, where R-α is -CN, and R2a, R2a, R4a and R4a are H.

5. Ophthalmic lens, according to any one of claims 1 to 4, characterized in that the compound of Formula (I) is such that: Ri is-CN, R2, R3, R4 and R5 are H, and X is-NRi5, R15, as defined in claim 1, in particular chosen from -(Ci-Ci2)alkyl, optionally substituted by one to three R16 groups, in particular chosen from halogen atoms, (C-iCi2)alkoxy, (C6-Ci8)aryl, or a compound of Formula a, as defined in claim 1, where Ria is -CN, and R2a, Raa, R4a and Rsa are H.

6. Ophthalmic lens, according to any one of claims 1 to 5, characterized in that the compound of Formula (I) is chosen from among the compounds of Formulas 1-1 to 1-7: 11 I 2 I 3 |-4 I ​​​​5 Petition 870260108441, dated 10 / 22 / 2026, page 62 / 139 5 / 10 IZ 7. Ophthalmic lens, according to any one of claims 1 to 6, characterized in that the compound of Formula (I) has a maximum absorption wavelength (λmax) equal to or less than 400 nm, as measured in a 20 ppm solution of the compound of Formula I in an organic solvent, in particular in tetrahydrofuran, said maximum absorption wavelength being situated, in particular, in the range of 350 to 400 nm, more particularly from 370 to 400 nm.

8. Ophthalmic lens, according to claim 7, characterized in that, at the maximum absorption wavelength (λmax), the compound of Formula (I) has a molar absorption extinction coefficient (ε) greater than 30,000 M'1cm'1, said molar absorption extinction coefficient (ε) being situated in particular in the range of 30,000 to 80,000 M'1cm'1, more particularly in the range of 30,000 to 70,000 M'1cm'1 and even more particularly in the range of 30,000 to 45,000 M'1cm'1.

9. Ophthalmic lens, according to any one of claims 1 to 8, characterized in that the compound of Formula (I) is included in the plastic base or in a separate layer coated onto a surface of the plastic base.

10. Ophthalmic lens, according to any one of claims 1 to 9, characterized in that the amount of compound of Formula (I) is in the range of 0.001 to 2%, in particular 0.001 to 1%, more particularly 0.001 to 0.1%, even more particularly 0.01 to 0.05%, by weight based on the weight of the plastic base when the compound of Formula (I) is included in the plastic base or on the weight of a separate layer when the compound of Formula (I) is included in a separate layer coated on a surface of the plastic base. Petition 870260108441, 22 / 10 / 2026, p. 63 / 139 6 / 10 11. Ophthalmic lens, according to any one of claims 1 to 10, characterized in that the ophthalmic lens further comprises a benzotriazole UV absorber or a mixture thereof, preferably a benzotriazole UV absorber selected from 2-(2-hydroxy-5-tert-octylphenyl)-2H-benzotriazole, 2-(3-tert-butyl-2-hydroxy-5-methylphenyl)-5-chloro-2H-benzotriazole and mixtures thereof, in particular wherein the total amount of benzotriazole UV absorber is in the range of 0.001 to 2%, in particular 0.01 to 1.5%, more particularly 0.1 to 1.25%, by weight based on the weight of the plastic base.

12. Ophthalmic lens, according to any one of claims 1 to 11, characterized in that the plastic base is a thermosetting or thermoplastic resin, in particular a thermosetting resin, in particular comprising a copolymer of at least one polythiol and a polyisocyanate, and / or in that the plastic base has a refractive index of 1.4 to 1.9, in particular of 1.49 to 1.

74.

13. Ophthalmic lens, according to any one of claims 1 to 12, characterized by having a UV cutoff greater than 403 nm, in particular comprised in the range of 403 to 420 nm, more particularly comprised in the range of 404 to 411 nm, and / or where the TvD65 transmittance of the ophthalmic lens is greater than 85%, in particular greater than 87%, and / or where the yellow index YI is less than 14, and / or where the BVC value B' is greater than 25%, in particular greater than 30%, more particularly greater than 35%.

14. Ophthalmic lens, according to any one of claims 1 to 13, characterized in that the optical cutoff change ΔUVcutoff after exposure of the ophthalmic lens for 40 hours to light in a Q-SUN Xe-3 xenon test chamber is less than 2%, in particular, less than 1%, and / or Petition 870260108441, dated 10 / 22 / 2026, page 64 / 139 7 / 10 in which the perceived color difference AEiab after exposure of the ophthalmic lens for 40 hours to light in a Q-SUN Xe-3 xenon test chamber is less than 2.5, in particular, less than 1.

15. Process for preparing the ophthalmic lens, as defined in any one of claims 1 to 14, characterized by comprising the steps of: a) providing monomers or oligomers from which the plastic base can be prepared; b) mixing the monomers or oligomers, the compound of Formula (I) and a suitable catalyst for the polymerization of the monomers and oligomers in order to form a polymerizable liquid composition; c) curing the polymerizable liquid composition.

16. Use of the compound of Formula (I), as defined in any one of claims 1 to 14, characterized in that it is in an ophthalmic lens for absorbing blue light.

17. Composition, characterized by comprising a plastic base and a compound of formula (IA), wherein: Ri is chosen from -CN, -CONH2, -CO2R6 or -SO2-(C1C-12)alkyl, R2 is, independently of R3, R4, and R5, chosen from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRn, N(Ri2)2, -NHCOR13, -NHSO2OR14, -NO2, -CN, (C1C-12)alkyl, (C1C-12)haloalkyl, (C2C-12)alkenyl, (C2C-12)alkynyl, (C1C-12)heteroalkyl, (C3C-12)cycloalkyl, (C3C-12)heterocycloalkyl, (Ce-Cijarila, (CeCi8)aryl-(Ci-Ci2)alkyl or heteroaryl-(Ci-Ci2)alkyl (with 5 to 10 members), R3, R4 and R5 are independently selected from H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8, -SORg, SO2R10, -NH2, -NHRn, -N(Ri2)2, -NHCOR13, -NHSO2ORu, -NO2i -CN, (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (C6-Ci8)aryl(Ci-Ci2)alkyl,heteroaryl (with 5 to 10 members) or heteroaryl-(Ci-Ci2)alkyl (with 5 to 10 members), X is NH, NR15, O or S, Re, R7, Re, Rg, R10, R11, R12, R13 θ Ru are independently selected from (Ci-Ci2)alkyl, (Ci-Ci2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (C6-Ci8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl-(Ci-Ci2)alkyl (with 5 to 10 members), R15 is chosen from (C1-C12)alkyl, (C2-C12)alkenyl, (C2C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to 10 members), heteroaryl-(C1-C12)alkyl (with 5 to 10 members), said alkyl being optionally substituted by one to three Rw groups, R16 is chosen from halogen atoms, (C1-C12)alkoxy, (C1-C18)aryl, or wherein R15 is a structure of Formula b: in which L is (C1-C12)alkylene, Ria is chosen from -CN,-CONH2, -CO2Rea or -SO2-(CiPetição 870260108441, dated 10 / 22 / 2026, page 66 / 139 9 / 10 Ci2) alkyl, R2a and, independently of R3a, R4a and R5a, mixed between H, F, Cl, Br, I, -OH, -ORza, -SH, -SR8a, -SORga, SO2Rioa, -NH2, -NHRiia, -N(Ri2a)2, -NHCORi3a, -NHSÜ2ORi4a, -NO2, -CN, (Ci-Ci2)alkyl, (CiCi2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyla, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (C6Ci8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to i0 members) or heteroaryl(Ci-Ci2)alkyl (with 5 to i0 members), R3a, R4a and R5a are independently selected between H, F, Cl, Br, I, -OH, -OR7, -SH, -SR8a, -SORga, SO2Rioa, -NH2, -NHRiia, N(Ri2a)2, -NHCORi3a, -NHSO2ORi4a, -NO2, -CN, (Ci-Ci2)alkyla, (CiCi2)haloalkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkyl, (Ci-Ci2)heteroalkyl, (C3-Ci2)cycloalkyl, (C3-Ci2)heterocycloalkyl, (C6-Ci8)aryl, (C6Ci8)aryl-(Ci-Ci2)alkyl, heteroaryl (with 5 to 10 members) or heteroaryl(Ci-Ci2)alkyl (with 5 to 10 members),R6a, R7a, R8a, Rga, Ri0a, Riia, Ri2a, Ri3a and Ri4a are independently selected from (C1-C12)alkyl, (C1-C12)haloalkyl, (C2C12)alkenyl, (C2-C12)alkynyl, (C1-C12)heteroalkyl, (C3-C12)cycloalkyl, (C3-C12)heterocycloalkyl, (C6-C18)aryl, (C6-C18)aryl-(C1-C12)alkyl, heteroaryl (with 5 to i0 members) or heteroaryl-(C1-C12)alkyl (with 5 to i0 members), wherein the aryl or heteroaryl groups are optionally substituted by one or more substituents, in particular by i or 2 substituents, said substituents being, in particular, selected from: • halogen, in particularly F or Cl, • carboxylic ester, in particular methyl ester or ethyl ester, • (C1-C12)alkyl, in particular methyl, ethyl or isopropyl, • (C1-C12)alkoxy, in particular methoxy or ethoxy, • carboxylic acid, Petition 870260108441, of 22 / 10 / 2026, page 67 / 139 10 / 10 • nitrile, • amine, in particular -NH2, NHCH3 or N(CH3)2, said plastic base,as defined in any of claims 1 to 12.

18. Use of a composition, as defined in claim 17, characterized by being in an optical article.

19. Compound, characterized by being chosen from: CN 1-7 or salts thereof. Petition 870260108441, dated 10 / 22 / 2026, p. 68 / 139